225 related articles for article (PubMed ID: 22684153)
1. Adherence to guidelines for the prescribing of double and triple combinations of antithrombotic agents.
Warlé-Van Herwaarden MF; Roukens M; Pop GA; Lamfers EJ; De Smet PA; Kramers C
Eur J Prev Cardiol; 2014 Feb; 21(2):231-43. PubMed ID: 22684153
[TBL] [Abstract][Full Text] [Related]
2. Prescribing patterns of antiplatelet agents are highly variable after lower extremity endovascular procedures.
Allemang MT; Rajani RR; Nelson PR; Hingorani A; Kashyap VS
Ann Vasc Surg; 2013 Jan; 27(1):62-7. PubMed ID: 22981017
[TBL] [Abstract][Full Text] [Related]
3. Risk of bleeding in patients with acute myocardial infarction treated with different combinations of aspirin, clopidogrel, and vitamin K antagonists in Denmark: a retrospective analysis of nationwide registry data.
Sørensen R; Hansen ML; Abildstrom SZ; Hvelplund A; Andersson C; Jørgensen C; Madsen JK; Hansen PR; Køber L; Torp-Pedersen C; Gislason GH
Lancet; 2009 Dec; 374(9706):1967-74. PubMed ID: 20006130
[TBL] [Abstract][Full Text] [Related]
4. Perioperative prophylactic antithrombotic strategies in vascular surgery: current practice in the Netherlands.
Wiersema A; Bruijninckx C; Reijnen M; Vos J; Van Delden O; Vahl A; Zeebregts C; Moll F
J Cardiovasc Surg (Torino); 2015 Feb; 56(1):119-25. PubMed ID: 23337406
[TBL] [Abstract][Full Text] [Related]
5. Discrepancy between guidelines for stroke prevention in atrial fibrillation and practice patterns in primary care. The nationwide French AFIGP survey.
Sabouret P; Bricard M; Hermann MA; Cotté FE; Deret-Bixio L; Rushton-Smith S
Arch Cardiovasc Dis; 2015 Nov; 108(11):544-53. PubMed ID: 26113478
[TBL] [Abstract][Full Text] [Related]
6. Predictors and time trends in clopidogrel and proton pump inhibitor coprescription with low-dose acetylsalicylic acid.
Cea Soriano L; Bueno H; Johansson S; García Rodríguez LA
Pharmacoepidemiol Drug Saf; 2012 May; 21(5):463-9. PubMed ID: 22298501
[TBL] [Abstract][Full Text] [Related]
7. Antithrombotic therapy in patients with non-valvular atrial fibrillation undergoing percutaneous coronary intervention: should we change our practice after the PIONEER AF-PCI and RE-DUAL PCI trials?
Duerschmied D; Brachmann J; Darius H; Frey N; Katus HA; Rottbauer W; Schäfer A; Thiele H; Bode C; Zeymer U
Clin Res Cardiol; 2018 Jul; 107(7):533-538. PubMed ID: 29679144
[TBL] [Abstract][Full Text] [Related]
8. Safety of the cardiac triple therapy: the experience of the Quebec Heart Institute.
Brulotte S; Sénéchal M; Poirier P; Nguyen CM; Lemieux A; Magne J; Bergeron S
Can J Cardiol; 2007 Oct; 23 Suppl B(Suppl B):80B-83B. PubMed ID: 17932593
[TBL] [Abstract][Full Text] [Related]
9. Rapid change in prescribing behavior in hospitals participating in get with the guidelines-stroke after release of the management of atherothrombosis with clopidogrel in high-risk patients (MATCH) clinical trial results.
Menon BK; Frankel MR; Liang L; Labresh KA; Ellrodt G; Hernandez AF; Fonarow GC; Schwamm LH; Smith EE;
Stroke; 2010 Sep; 41(9):2094-7. PubMed ID: 20634476
[TBL] [Abstract][Full Text] [Related]
10. Long-term vitamin K antagonists treatment patterns of Non-Valvular Atrial Fibrillation (NVAF): a population-based cohort study.
Renoux C; Coulombe J; Suissa S
BMC Cardiovasc Disord; 2016 May; 16():84. PubMed ID: 27160254
[TBL] [Abstract][Full Text] [Related]
11. Antithrombotic drugs and subarachnoid haemorrhage risk. A nationwide case-control study in Denmark.
Pottegård A; García Rodríguez LA; Poulsen FR; Hallas J; Gaist D
Thromb Haemost; 2015 Nov; 114(5):1064-75. PubMed ID: 26202836
[TBL] [Abstract][Full Text] [Related]
12. Association of Antithrombotic Drug Use With Subdural Hematoma Risk.
Gaist D; García Rodríguez LA; Hellfritzsch M; Poulsen FR; Halle B; Hallas J; Pottegård A
JAMA; 2017 Feb; 317(8):836-846. PubMed ID: 28245322
[TBL] [Abstract][Full Text] [Related]
13. Compliance with antithrombotic prescribing guidelines for patients with atrial fibrillation--a nationwide descriptive study in Taiwan.
Lin LJ; Cheng MH; Lee CH; Wung DC; Cheng CL; Kao Yang YH
Clin Ther; 2008 Sep; 30(9):1726-36. PubMed ID: 18840379
[TBL] [Abstract][Full Text] [Related]
14. Triple antithrombotic therapy following an acute coronary syndrome: prevalence, outcomes and prognostic utility of the HAS-BLED score.
Smith JG; Wieloch M; Koul S; Braun OÖ; Lumsden J; Rydell E; Ohman J; Scherstén F; Svensson PJ; van der Pals J
EuroIntervention; 2012 Oct; 8(6):672-8. PubMed ID: 23086784
[TBL] [Abstract][Full Text] [Related]
15. Early treatment for non-ST-segment elevation acute coronary syndrome is associated with appropriate discharge care.
Fermann GJ; Raja AS; Peterson ED; Roe MT; Hoekstra JW; Milford-Beland S; Diercks DB; Pollack CV; Peacock WF; Summers R; Ohman EM; Gibler WB
Clin Cardiol; 2009 Sep; 32(9):519-25. PubMed ID: 19743495
[TBL] [Abstract][Full Text] [Related]
16. Real-world clopidogrel utilization in acute coronary syndromes: patients selection and outcomes in a single-center experience.
Castini D; Persampieri S; Cazzaniga S; Ferrante G; Centola M; Lucreziotti S; Salerno-Uriarte D; Sponzilli C; Carugo S
Ther Adv Cardiovasc Dis; 2017 Dec; 11(12):323-331. PubMed ID: 29134853
[TBL] [Abstract][Full Text] [Related]
17. Antiplatelet and anticoagulation therapy after revascularization for lower extremity artery disease: a national survey and literature overview.
Ipema J; Brand AR; DE Borst GJ; DE Vries JP; ÜnlÜ Ç
J Cardiovasc Surg (Torino); 2021 Feb; 62(1):59-70. PubMed ID: 33112125
[TBL] [Abstract][Full Text] [Related]
18. Utilization of evidence-based therapy for the secondary prevention of acute coronary syndromes in Australian practice.
Vermeer NS; Bajorek BV
J Clin Pharm Ther; 2008 Dec; 33(6):591-601. PubMed ID: 19138236
[TBL] [Abstract][Full Text] [Related]
19. [Secondary prevention with clopidogrel or acetylsalicylic acid after acute cerebrovascular event. Health services research study of private primary care specialists].
Sander D; Schwertfeger M; Köfüncü E; Diehm C; Pittrow D
Dtsch Med Wochenschr; 2008 Sep; 133(36):1773-8. PubMed ID: 18767003
[TBL] [Abstract][Full Text] [Related]
20. Effects of a novel platelet nitric oxide donor (LA816), aspirin, clopidogrel, and combined therapy in inhibiting flow- and lesion-dependent thrombosis in the porcine ex vivo model.
Vilahur G; Segalés E; Salas E; Badimon L
Circulation; 2004 Sep; 110(12):1686-93. PubMed ID: 15381660
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
